{"ticker": {"uuid": "897bc5d3-fde4-4979-90b4-ea8aa4b74697", "symbol": "ROIV", "name": "Roivant Sciences Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders", "summary": "Roivant Sciences recently secured a $2.25 billion settlement with Moderna, resolving patent-infringement litigation. Concurrent with this, the company reported positive clinical results for IMVT-1402 in rheumatoid arthritis and received Breakthrough Therapy Designation for brepoc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/what-roivant-sciences-roivs-225-billion-moderna-settlement-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-20T16:40:34", "published_display": "20 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress", "summary": "Roivant Sciences (ROIV) has garnered attention due to a $2.25 billion settlement with Moderna, positive IMVT-1402 rheumatoid arthritis data, and Breakthrough Therapy Designation for brepocitinib. The stock is currently trading at $31.43, which analysts estimate to be 19.5% underv", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-stock-could-be-195-undervalued-after-m/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-19T13:09:29", "published_display": "19 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fidelity Advisor Biotechnology Fund's Roivant Sciences Ltd(ROIV) Holding History", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPdG9UczVleTBiNUhVMzBBbzZ0REp0d1U1TTVrbFEzOEM2Y2htY2ZoY0phQWt6V3QxZmEtdGpaZ3lteXdhcHFSWWtMOEtEemlVcldjUXFTZjJBRUd4LWFjZ1JzZ3BfVTBxQ2hfcWJmVWpNYmxSXzJzbDZsQ2ZLUmlhVW5NS0NOT0JvTVMycm1ZLU4?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:53:46+00:00", "published_display": "18 Jun 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd (ROIV) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE1Ra1h6OXd4SVMwXzhFNmpPXzdXRWotXzFqQ1YyTG9yYTY1UDlLdE14Y3IyYTBRc2RlckFHdExFcFRRMFdHTlVkTWhuVUFtMFNtV25Ca051dlQ5LXBkenI2Mm9acWltLVdNM3pOZkY3VWY?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T01:23:30+00:00", "published_display": "18 Jun 2026 01:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd (ROIV) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Roivant Sciences Ltd (ROIV), highlighting its current risk score and market performance indicators. With a risk assessment score of 8.62, ROIV ranks 23 out of 157 in the Pharmaceuticals industry, indicating a slightly elevated risk prof", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-roiv/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:34", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV)", "summary": "This article summarizes recent analyst ratings for three healthcare stocks: enGene Holdings (ENGN), Medtronic (MDT), and Roivant Sciences (ROIV). Analysts have mixed opinions, with enGene Holdings receiving a \"Hold\" from Guggenheim and a \"Moderate Buy\" consensus, Medtronic gettin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MDT/pressreleases/2511262/analysts-opinions-are-mixed-on-these-healthcare-stocks-engene-holdings-engn-medtronic-mdt-and-roivant-sciences-roiv/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T00:39:01", "published_display": "18 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd (ROIV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Roivant Sciences Ltd's (ROIV) revenue breakdown for FY2025Q1. The primary business segment contributing revenue is VTAMA, generating $55.13 million. All reported revenue is attributed to the United States region.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-roiv/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:34", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory", "summary": "Roivant Sciences Ltd. (NASDAQ: ROIV) is highlighted as a top growth stock in oversold territory after reporting strong financial results for FY2026, including $4.3 billion in cash and a significant settlement with Moderna. The company has a robust clinical pipeline with upcoming ", "url": "https://www.insidermonkey.com/blog/here-is-why-roivant-roiv-is-one-of-the-best-growth-stocks-trading-in-oversold-territory-1782970/", "source_name": "Insider Monkey", "published_at": "2026-06-17T09:46:00", "published_display": "17 Jun 2026 09:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40", "summary": "Piper Sandler has reiterated its Buy rating on Roivant Sciences (ROIV.US) and maintained its price target of $40. This indicates a continued positive outlook on the company's stock performance and valuation by the investment bank.", "url": "https://www.moomoo.com/news/post/71598990/piper-sandler-maintains-roivant-sciences-roivus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-16T13:11:32", "published_display": "16 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Best Beaten Down Growth Stocks to Buy Right Now", "summary": "This article identifies Roivant Sciences Ltd. (NASDAQ: ROIV) as a key \"beaten down\" growth stock, highlighting its strong financial position with $4.3 billion in cash and marketable securities and a significant $2.25 billion settlement with Moderna. The company also boasts a prom", "url": "https://www.insidermonkey.com/blog/12-best-beaten-down-growth-stocks-to-buy-right-now-1779424/5", "source_name": "Insider Monkey", "published_at": "2026-06-15T23:09:52", "published_display": "15 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 29.97% Upside in Biotech Innovation", "summary": "Roivant Sciences Ltd. (ROIV) is analyzed as a promising biotech company with a potential 29.97% upside, driven by its innovative pipeline in autoimmune and cardiopulmonary diseases and strong analyst support. Despite financial challenges common to clinical-stage biotech firms, su", "url": "https://www.directorstalkinterviews.com/roivant-sciences-ltd-roiv-stock-analysis-exploring-a-potential-29-97-upside-in-biotech-innovation/4121253782", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T10:20:00", "published_display": "15 Jun 2026 10:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV", "summary": "Te Ahumairangi Investment Management Ltd reduced its stake in Roivant Sciences Ltd. by 33.6% in the fourth quarter of the previous year, selling 54,800 shares. Despite this, Wall Street analysts maintain a \"Moderate Buy\" consensus rating for Roivant Sciences with an average price", "url": "https://www.marketbeat.com/instant-alerts/filing-te-ahumairangi-investment-management-ltd-decreases-position-in-roivant-sciences-ltd-roiv-2026-06-12/", "source_name": "MarketBeat", "published_at": "2026-06-12T09:40:21", "published_display": "12 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gilead-sciences-inc-gild-top-010008074.html", "source_name": "Insider Monkey", "published_at": "2026-06-11T01:00:08+00:00", "published_display": "11 Jun 2026 01:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV", "summary": "Clearbridge Investments LLC increased its stake in Roivant Sciences Ltd. by 7.7% in the fourth quarter, purchasing an additional 141,549 shares to bring its total holding to nearly 2 million shares valued at $42.8 million. Roivant Sciences has experienced significant institutiona", "url": "https://www.marketbeat.com/instant-alerts/filing-clearbridge-investments-llc-boosts-stock-holdings-in-roivant-sciences-ltd-roiv-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T21:09:38", "published_display": "10 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV", "summary": "Bank of New York Mellon Corp reduced its stake in Roivant Sciences Ltd. by 37.3% in the fourth quarter, yet still holds 2.9 million shares valued at approximately $63 million. Despite a recent earnings beat on EPS, revenue fell short of estimates, and the company continues to pos", "url": "https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-has-63-million-stock-holdings-in-roivant-sciences-ltd-roiv-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T21:09:38", "published_display": "10 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV", "summary": "TD Asset Management Inc. significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during Q4, purchasing an additional 235,176 shares, bringing its total to 551,376 shares valued at $12.0 million. Other major institutions like Vanguard and UBS also raised their hol", "url": "https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-purchases-235176-shares-of-roivant-sciences-ltd-roiv-2026-06-09/", "source_name": "MarketBeat", "published_at": "2026-06-09T21:39:03", "published_display": "09 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)", "summary": "Guggenheim maintained a Buy rating on Roivant Sciences Ltd. (ROIV) and increased its price target to $36, following the company's fiscal Q4 earnings and pipeline updates. Citi also raised its price target to $42 and reiterated a Buy rating, citing potential upside from second-hal", "url": "https://www.insidermonkey.com/blog/guggenheim-remains-bullish-on-roivant-sciences-ltd-roiv-1777926/", "source_name": "Insider Monkey", "published_at": "2026-06-09T18:10:28", "published_display": "09 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11", "summary": "Roivant Sciences Ltd. presented at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation, featuring analyst Corinne Jenkins, focused on insights and updates regarding the company. The full transcript of the event is available to subscribers.", "url": "https://www.marketscreener.com/news/transcript-roivant-sciences-ltd-presents-at-goldman-sachs-47th-annual-global-healthcare-conferenc-ce7f5cdadf8bf02c", "source_name": "www.marketscreener.com", "published_at": "2026-06-09T12:25:00", "published_display": "09 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CenterBook Partners LP Purchases 364,390 Shares of Roivant Sciences Ltd. $ROIV", "summary": "CenterBook Partners LP significantly increased its stake in Roivant Sciences Ltd. by 147.3% in the fourth quarter, buying 364,390 shares to bring its total holdings to 611,833 shares valued at approximately $13.3 million. Wall Street analysts maintain a \"Moderate Buy\" rating for ", "url": "https://www.marketbeat.com/instant-alerts/filing-centerbook-partners-lp-purchases-364390-shares-of-roivant-sciences-ltd-roiv-2026-06-08/", "source_name": "MarketBeat", "published_at": "2026-06-08T21:39:03", "published_display": "08 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of \"Moderate Buy\" by Brokerages", "summary": "Roivant Sciences Ltd. (NASDAQ:ROIV) has received a \"Moderate Buy\" consensus rating from brokerages, with an average 1-year price target of $33.59. Various firms, including Citigroup and Guggenheim, recently raised their price targets for ROIV, despite a slight downgrade from Weis", "url": "https://www.marketbeat.com/instant-alerts/roivant-sciences-ltd-nasdaqroiv-given-consensus-rating-of-moderate-buy-by-brokerages-2026-06-04/", "source_name": "MarketBeat", "published_at": "2026-06-06T09:40:21", "published_display": "06 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ROIV Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article analyzes the financial performance of Roivant Sciences Ltd (ROIV), focusing on its revenue breakdown, profitability margins, and a comparison with competitors like INSM and INCY. ROIV exhibits a strong gross margin but negative operating and net margins, alongside a ", "url": "https://intellectia.ai/en/stock/ROIV/financials", "source_name": "Intellectia AI", "published_at": "2026-06-02T21:39:58", "published_display": "02 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Roivant\u2019s (ROIV) Profitable Quarter and $982 Million Shelf Filing Just Reframe Its Capital Strategy?", "summary": "Roivant Sciences (ROIV) recently reported a profitable fourth quarter with net income of US$302.99 million, despite only US$2.52 million in sales, contrasting with a full-year net loss. Concurrently, the company filed a US$981.62 million shelf registration for potential share iss", "url": "https://www.sahmcapital.com/news/content/did-roivants-roiv-profitable-quarter-and-982-million-shelf-filing-just-reframe-its-capital-strategy-2026-06-01", "source_name": "Sahm", "published_at": "2026-06-02T05:41:13", "published_display": "02 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (ROIV) Stock Report: Analyzing The 30.18% Potential Upside", "summary": "Roivant Sciences Ltd. (ROIV) is gaining investor attention with a market capitalization of $21.57 billion and a strong analyst consensus pointing to a 30.18% potential upside. The biopharmaceutical company, based in the UK, is focused on drug discovery and development, with lead ", "url": "https://www.directorstalkinterviews.com/roivant-sciences-ltd-roiv-stock-report-analyzing-the-30-18-potential-upside/4121252748", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T10:18:00", "published_display": "01 Jun 2026 10:18", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum", "summary": "Roivant Sciences (ROIV) is in focus after strong Phase 2b results for IMVT-1402 and recent earnings, leading to a significant year-to-date share price return. The company is considered 16.3% undervalued by some narratives, with a fair value target of $35.71, driven by a late-stag", "url": "https://www.sahmcapital.com/news/content/roivant-sciences-roiv-valuation-after-strong-imvt-1402-data-and-late-stage-pipeline-momentum-2026-05-29", "source_name": "Sahm", "published_at": "2026-05-29T18:09:20", "published_display": "29 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. - Common Shares (NQ: ROIV)", "summary": "This article provides financial news and press releases related to Roivant Sciences Ltd. (NQ: ROIV). It highlights recent stock performance, company announcements such as the unveiling of Priovant Therapeutics and ongoing registrational studies, and the announcement of 2021 Open ", "url": "https://markets.financialcontent.com/stocks/quote/news?Symbol=NQ%3AROIV&CurrentPage=3&ChannelType=PRESSRELEASES&CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2026-05-29T15:10:05", "published_display": "29 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (NasdaqGS:ROIV) Stock Forecast & Analyst Predictions", "summary": "Roivant Sciences (NasdaqGS:ROIV) is forecast to grow earnings and revenue by 50% and 53.9% per annum respectively, although it is expected to remain unprofitable for the next three years. Analysts have frequently updated price targets and revenue estimates based on clinical trial", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/future", "source_name": "Simply Wall Street", "published_at": "2026-05-27T20:39:53", "published_display": "27 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40", "summary": "J.P. Morgan has reiterated its Buy rating on Roivant Sciences (ROIV.US) and increased its target price for the company's stock to $40. This move signals continued confidence from the financial institution regarding Roivant Sciences' future performance and valuation.", "url": "https://www.moomoo.com/news/post/70586721/jp-morgan-maintains-roivant-sciences-roivus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-05-27T15:10:05", "published_display": "27 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that a Roivant Sciences insider sold shares totaling $6,054,000. This transaction could be of interest to investors tracking insider activity and fundamental company developments.", "url": "https://www.moomoo.com/news/post/70552057/roivant-sciences-insider-sold-shares-worth-6054000-according-to-a", "source_name": "Moomoo", "published_at": "2026-05-26T14:08:42", "published_display": "26 May 2026 14:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOOUZOUXVDdmE1VHk0QzlMbU5oN3cyNzUwUU5LckV0QmZzZk0zblR5WUVHQVRnWlJfMVhHd1hNZ3JXVmZyT0JSUUNFdGtCYWJybVQ3MW9LMHoxb3VQWjB2dlE1Mmgwbl93cGdNR041eVpBQW01YmdjODl1aUFOSXlyOGR3R1dWVmEwVjA0bGhpakJWNlFaTDF1UGJhXzU4Q1FNa1JpOG1JSHFFUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Raises its Price Target on Roivant Sciences (ROIV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPLVBwYjZDMkNWTTNfS1oyUXZCSjJQeGY2cmU4SkV5T0ptTnFQOHNMc2g1NWowVHkyVEt4UmhHblI0aXFXQ2podVFxS0FlaTg1ZThPa1JpU0FBZUF6ZkZtQXV3TUVUeDRrSHZuT1l4cVkwcGVKcGNrTkpTNmFtdW9NTUE3ZkFTb3I3YTRFN1lQV09zWTlGVWpPYg?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Litigation Windfall Driving Roivant Sciences\u2019 Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVEt0ZnhaaUZlQ3ozNVpIb2JPeTVtTUhscnAzZE1GTlo5Nng0SXExOHMtMXNaTXd2NHBpdXpwTWFKcUkxSExVYjB4dzlxS2c0bDdraU5XejhicE5xTWNxQjlTX1Y5ZVoybktJbW1WMWFRR3ZsY082SFZheGdUQWx3czdHOWJCODhXNEQxZFMtZUhjZGRlY096R2stSVVPRFZUWTVRYm82ZkU3b0dxTnc?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen raises Roivant Sciences stock price target to $41 on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPcTJuaFlqWlkwVUphUkZGZk5JQlMxTHQ2RFdMSmd2X0hBUlpMUGQtZmFWR3NVbGNvOGlPRDdKcXRoVEhrNThrazRSN0s2eWlBR2syV2F5M21pdENDNzRSbmhxaVUxYm1SSWZPTG96UUVGY0t3QWFnOGR1bTltempMSVlqRE9ENUFFSFNVNUJmTnEzdzhmSVpxVm1jb1JxX3lZMDZPc2lIYzRPYjlRYUxrWEhCYU5xemlJc1dfeGJGaUFYZ0NmTGY1XzFERQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant (ROIV) Climbs 15% on Swing to Profits", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOX08xOE5IRGwzT2ZjV0g2ZVJRYmZ1QUh2Qm1yS0xITVQwbks4VzhLcUZyUnpZT29vdWl4SzVUY1VXRVdZdW1SVGRJVUVMaldPSnJFNVNrRE9vMWNHbGtFbV84M3ZCMFZqblhORWxJUGVfYnI4MXpEbHR5dmlhejMwNWhhUDM1NmJKb1UxbERLZUxzVXE4ZmJwRw?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant (NASDAQ: ROIV) books $770M legal gain and holds $4.3B cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOSHNaMmZHLV9oSHg5cHBhNVgyRllmUnBsLUtFbE4yWEM4TFR2aks3SHR5b0NaUGl4NUh3VEVEQVBXeFJXYXBZRDNJYUVlN1VDQ0haOW1wYThQV01feWxHX1NlaFJfcC01TjZ3YzFFNUlRZU5ETTIzZkJiYmhDeExvdzNpaVpLWktHVFlLWjhGWXB4VE94NUt4QXcwY3FpWUtTcUlKWjBybVJ5WUpGQUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTzJXMDZaS21Hck1pbDg2RDRjM0w2VGdZSFBrTjFram90TGFEWUYyZkhidXpzZ25hYW54YnlyTUZHMmtBbG9POUpOUW53S3NFcGJiTVNrMDdJUTg1cU1WckVOUlh2NmZSQTFKeDlFOHNldmRkaktvSnNFSU5SaVdreVVuQUVMdTB1em5CaS1WU2VRZGx2YzhqYnpwUXlPZWhuaW1OVk13?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVXh3WTJ1cEJrZUk5UmQ1V3l6aFlyT201ZHI5Tk5KNFNTOFV2ZFVvM3pzOTVSeFdpdTF0cGRMOEJhNVYtUllJWWNHWXFWQjA1RVFFVFBVRnBrTzRHT3J6TEZjNTRhallvUTA3N2pRRUtWSFhleFUtYzYwdTVkM2tLSVNVTUhhZVZNTHRLU0wtOS1WMUk5RGVGTkFjSDlFTjUxSEpv?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Roivant Sciences (ROIV) Valuation After Encouraging Phase 2 Brepocitinib Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQU1ZHNHpTbHJkakhBX21FMnREVlF2bnNYUEUyOUlKRFRwbHdiZU1ZWURBYTNVWFJ2VTJSejJzNHVUc3A2RVJ4c2QtWTNiSXptTE0xeEROM05YNEZEWHJSZ1VOdmFraHJYdjlUck9mc0Z4TDA0UzliUzNRN0JIdlUwT01jQl9DYm1TWUw0LTM4TFNfQ2s3akhmVkdSVVBpX25KNmpF?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNTWRkaTZzbDJGckxXVFl6QVJzZURfNXNsenRwSUVtdHZGeEk0VnVZczAxQUZva183dk9QZjgwcjFaajRpTDhrcXN1TFliWVVIZUxmTnFmcTE1aDN0NVRhUHVzNUxMbm55OEhOZkw3SGQzUlZyMG5IdlhadkluZkNsUnpkU2R1X0JIaUd2N0F5ZndNU0tzR2VwYWFB?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bernstein initiates Roivant Sciences stock with outperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxON2JxSmhwWHJMWWVDOEZzT3lxaUlvaC1mWllmYlJRMGZzSVVoZFRoZHJDSXVabkZkekZxMGw0TkFXT1R1OFJPYXlHZzI1MFBPcXc5T2dFUWE5UUFpZEJ0V1R3eGo2WVVNalh5a191UzA4cndQall1cUdScUl1dlg3aDNBN3NjcnIxOENHR3lzdGpDWXgyRVNnVE9Tek9BZk5ydDh1TVByTzZzang1SVFRZWh0TXhpNS02UnBVeGVTaktvZmc?oc=5", "source_name": "Investing.com", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNRlBObFdWb2lyLWJhN3V3NWpNZ3JIZjFHSXZxRS0tcVFuN1RuRzRWamlJQjhEZS1uMEVzZWQ4cllTTUNfa0YtamxTLUpTU0U4R1dhMEc3S1RNOXkyazJVUEJ3b2hQTVAwQWtxNS1zLUEybVpOYTBRbHAySFBYREtGbXBnazMtNEtRdnVJV2lvaF9kYlVWWTM0MVZ1UGh6QmdyQmdaaHFlMWJaNHNuOHA4MUR3cTd5MkRsVGU5bUdsTkJGajQyVGZB?oc=5", "source_name": "Investing.com", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant unit lands up to $2.25B in Moderna COVID vaccine patent deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOOTR1S3F2aTQ4QVltTDN1MEl5VFhnU2FtZjVfUUpZNDBmY2RnNFFLUG5hTk5jN1A2cjAzRG1SSDdzamJsM2ZsMW9jcTJpSFpNcHRrLXFKZVFxelJ6Ql9MUG1wdm9VeTR0M2g0VFhBX2NobVV3UjB2ZTJlUzY5Vnl6UVhDbFZNTjctRmNyaTZBRGxnSEZ2MzRQeGpDWGVNMTFRTVEzM08tT2xCRXNVOXlBVXlZZTVTODVWSjYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates Roivant Sciences stock rating on pipeline progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPTUtyUVpEMEZUZXFwNkllaml0N2oxUHZHNFQ0bEpHRUtNWWJ6dFlEOTlUTGhETkE1bHk3WmVDT0Z0QWVsT01xbFpPN3Q1WkFZZmJQakdsVi0ycVROdzJEUXVMTktSTTd6c0dkNlJISnNjRlhjaHV3TkxMeF9vSjY4b0tLelRheVJOV2o1Ykk1RGxDTVJDYzBtR1diZWhhZXd3ak5zZS1OamlOcnNmUFZrWlZ3dGZwRjB6MkV3dUhSV2dZWkRpOUd0OF9pZw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSWtKOGRYTmJZeVlXd0pyVlVKS05KVDZuaEotaU1TbWlpdkFnUzB3Slh6OTJXanV6OGtTakdKRGp6WjNuM2V3bVU3dUNxRE1lWndWdWlnRnRMWWRjVEs1eElwdXJqYlRNSUlPTHRULUI0MjRKSkpnRzlzLU84eDcyWjFMUjZCUWhtVnlj?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPbUtkZlJPS3dLOERyUm5lZGRWZXgzYkswdGJHNWhHQW9VSUZ1ekxERFJXZmhxWklkMWtqM2NVNnNQLUY2VXJISGFMdUhJblNXY2VFMTdmZDREaXlkbUZLa2FhQWEyblJrT25ybkpvVklpeHhkamt4azVPSWtxTFhwTEF5ZDU1S2tES2RYNWhpUy1TX3QwN01IQ3pvN2hnYjdvdHYySTBLTUtXNUY0S3VLS2d3Q2RoWjA?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNQkZuVmMtNWpvdjFsN2VGZk9xdU1wdGZycmcwbXhDZFVWM0tRWnI3UFAxN01QdXhGSFNoV1RCY0NPQ1RLRjE1MHduc3NqZTN5RnJnT2FDMXN5RGZaaHhhVXF5dVd3R3JDZUlYaURSbDZjOVVkcVZZaG85RHR3U09IZjNjc3hHaHFsb19tUm1nLWVWaUhoMUVsczRnaklZMFJhcmlfRTdlc1gzSFJtYXJ1QWJ3SFpPR0Voend0N2J3MWw4Y0YzZG9ScnVfbFlPWC1FYm1LRXptVTFDdw?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOaDBEUURhTU04V0hHaEZLTXFGQTN4SU9YckJnMWN6V0FWVHY2Q0dVMmEwVEc0V3EtU0xWUmh4TTZZSkx0YUcxRHo3TWI2Z0lKekxyUTR1QlZOUDZJOHY0UzZicmw0R3RmTHNEZ1JhdGZDUUgtTWFlM0Q5dkh3WlVfR053VnFKOVl4WVpEM1hNdFJGY0R3bDQ0dVhYa3BrQ181LVNpYjU0dFV1eGtyTTUwcFBCbU5zZjl6ZnpCZDRRaWhZU2s3dEl3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders", "summary": "Roivant Sciences recently secured a $2.25 billion settlement with Moderna, resolving patent-infringement litigation. Concurrent with this, the company reported positive clinical results for IMVT-1402 in rheumatoid arthritis and received Breakthrough Therapy Designation for brepoc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/what-roivant-sciences-roivs-225-billion-moderna-settlement-a/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-20T16:40:34", "published_display": "20 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress", "summary": "Roivant Sciences (ROIV) has garnered attention due to a $2.25 billion settlement with Moderna, positive IMVT-1402 rheumatoid arthritis data, and Breakthrough Therapy Designation for brepocitinib. The stock is currently trading at $31.43, which analysts estimate to be 19.5% underv", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-stock-could-be-195-undervalued-after-m/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-19T13:09:29", "published_display": "19 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fidelity Advisor Biotechnology Fund's Roivant Sciences Ltd(ROIV) Holding History", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPdG9UczVleTBiNUhVMzBBbzZ0REp0d1U1TTVrbFEzOEM2Y2htY2ZoY0phQWt6V3QxZmEtdGpaZ3lteXdhcHFSWWtMOEtEemlVcldjUXFTZjJBRUd4LWFjZ1JzZ3BfVTBxQ2hfcWJmVWpNYmxSXzJzbDZsQ2ZLUmlhVW5NS0NOT0JvTVMycm1ZLU4?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-18T07:53:46+00:00", "published_display": "18 Jun 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd (ROIV) Institutional Confidence", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE1Ra1h6OXd4SVMwXzhFNmpPXzdXRWotXzFqQ1YyTG9yYTY1UDlLdE14Y3IyYTBRc2RlckFHdExFcFRRMFdHTlVkTWhuVUFtMFNtV25Ca051dlQ5LXBkenI2Mm9acWltLVdNM3pOZkY3VWY?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T01:23:30+00:00", "published_display": "18 Jun 2026 01:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd (ROIV) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Roivant Sciences Ltd (ROIV), highlighting its current risk score and market performance indicators. With a risk assessment score of 8.62, ROIV ranks 23 out of 157 in the Pharmaceuticals industry, indicating a slightly elevated risk prof", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-roiv/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T01:40:34", "published_display": "18 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN), Medtronic (MDT) and Roivant Sciences (ROIV)", "summary": "This article summarizes recent analyst ratings for three healthcare stocks: enGene Holdings (ENGN), Medtronic (MDT), and Roivant Sciences (ROIV). Analysts have mixed opinions, with enGene Holdings receiving a \"Hold\" from Guggenheim and a \"Moderate Buy\" consensus, Medtronic gettin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MDT/pressreleases/2511262/analysts-opinions-are-mixed-on-these-healthcare-stocks-engene-holdings-engn-medtronic-mdt-and-roivant-sciences-roiv/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T00:39:01", "published_display": "18 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd (ROIV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a brief overview of Roivant Sciences Ltd's (ROIV) revenue breakdown for FY2025Q1. The primary business segment contributing revenue is VTAMA, generating $55.13 million. All reported revenue is attributed to the United States region.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-roiv/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T22:40:34", "published_display": "17 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory", "summary": "Roivant Sciences Ltd. (NASDAQ: ROIV) is highlighted as a top growth stock in oversold territory after reporting strong financial results for FY2026, including $4.3 billion in cash and a significant settlement with Moderna. The company has a robust clinical pipeline with upcoming ", "url": "https://www.insidermonkey.com/blog/here-is-why-roivant-roiv-is-one-of-the-best-growth-stocks-trading-in-oversold-territory-1782970/", "source_name": "Insider Monkey", "published_at": "2026-06-17T09:46:00", "published_display": "17 Jun 2026 09:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $40", "summary": "Piper Sandler has reiterated its Buy rating on Roivant Sciences (ROIV.US) and maintained its price target of $40. This indicates a continued positive outlook on the company's stock performance and valuation by the investment bank.", "url": "https://www.moomoo.com/news/post/71598990/piper-sandler-maintains-roivant-sciences-roivus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-16T13:11:32", "published_display": "16 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Best Beaten Down Growth Stocks to Buy Right Now", "summary": "This article identifies Roivant Sciences Ltd. (NASDAQ: ROIV) as a key \"beaten down\" growth stock, highlighting its strong financial position with $4.3 billion in cash and marketable securities and a significant $2.25 billion settlement with Moderna. The company also boasts a prom", "url": "https://www.insidermonkey.com/blog/12-best-beaten-down-growth-stocks-to-buy-right-now-1779424/5", "source_name": "Insider Monkey", "published_at": "2026-06-15T23:09:52", "published_display": "15 Jun 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a Potential 29.97% Upside in Biotech Innovation", "summary": "Roivant Sciences Ltd. (ROIV) is analyzed as a promising biotech company with a potential 29.97% upside, driven by its innovative pipeline in autoimmune and cardiopulmonary diseases and strong analyst support. Despite financial challenges common to clinical-stage biotech firms, su", "url": "https://www.directorstalkinterviews.com/roivant-sciences-ltd-roiv-stock-analysis-exploring-a-potential-29-97-upside-in-biotech-innovation/4121253782", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T10:20:00", "published_display": "15 Jun 2026 10:20", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Te Ahumairangi Investment Management Ltd Decreases Position in Roivant Sciences Ltd. $ROIV", "summary": "Te Ahumairangi Investment Management Ltd reduced its stake in Roivant Sciences Ltd. by 33.6% in the fourth quarter of the previous year, selling 54,800 shares. Despite this, Wall Street analysts maintain a \"Moderate Buy\" consensus rating for Roivant Sciences with an average price", "url": "https://www.marketbeat.com/instant-alerts/filing-te-ahumairangi-investment-management-ltd-decreases-position-in-roivant-sciences-ltd-roiv-2026-06-12/", "source_name": "MarketBeat", "published_at": "2026-06-12T09:40:21", "published_display": "12 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gilead-sciences-inc-gild-top-010008074.html", "source_name": "Insider Monkey", "published_at": "2026-06-11T01:00:08+00:00", "published_display": "11 Jun 2026 01:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Clearbridge Investments LLC Boosts Stock Holdings in Roivant Sciences Ltd. $ROIV", "summary": "Clearbridge Investments LLC increased its stake in Roivant Sciences Ltd. by 7.7% in the fourth quarter, purchasing an additional 141,549 shares to bring its total holding to nearly 2 million shares valued at $42.8 million. Roivant Sciences has experienced significant institutiona", "url": "https://www.marketbeat.com/instant-alerts/filing-clearbridge-investments-llc-boosts-stock-holdings-in-roivant-sciences-ltd-roiv-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T21:09:38", "published_display": "10 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of New York Mellon Corp Has $63 Million Stock Holdings in Roivant Sciences Ltd. $ROIV", "summary": "Bank of New York Mellon Corp reduced its stake in Roivant Sciences Ltd. by 37.3% in the fourth quarter, yet still holds 2.9 million shares valued at approximately $63 million. Despite a recent earnings beat on EPS, revenue fell short of estimates, and the company continues to pos", "url": "https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-has-63-million-stock-holdings-in-roivant-sciences-ltd-roiv-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T21:09:38", "published_display": "10 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Asset Management Inc Purchases 235,176 Shares of Roivant Sciences Ltd. $ROIV", "summary": "TD Asset Management Inc. significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during Q4, purchasing an additional 235,176 shares, bringing its total to 551,376 shares valued at $12.0 million. Other major institutions like Vanguard and UBS also raised their hol", "url": "https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-purchases-235176-shares-of-roivant-sciences-ltd-roiv-2026-06-09/", "source_name": "MarketBeat", "published_at": "2026-06-09T21:39:03", "published_display": "09 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)", "summary": "Guggenheim maintained a Buy rating on Roivant Sciences Ltd. (ROIV) and increased its price target to $36, following the company's fiscal Q4 earnings and pipeline updates. Citi also raised its price target to $42 and reiterated a Buy rating, citing potential upside from second-hal", "url": "https://www.insidermonkey.com/blog/guggenheim-remains-bullish-on-roivant-sciences-ltd-roiv-1777926/", "source_name": "Insider Monkey", "published_at": "2026-06-09T18:10:28", "published_display": "09 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 11", "summary": "Roivant Sciences Ltd. presented at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The presentation, featuring analyst Corinne Jenkins, focused on insights and updates regarding the company. The full transcript of the event is available to subscribers.", "url": "https://www.marketscreener.com/news/transcript-roivant-sciences-ltd-presents-at-goldman-sachs-47th-annual-global-healthcare-conferenc-ce7f5cdadf8bf02c", "source_name": "www.marketscreener.com", "published_at": "2026-06-09T12:25:00", "published_display": "09 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CenterBook Partners LP Purchases 364,390 Shares of Roivant Sciences Ltd. $ROIV", "summary": "CenterBook Partners LP significantly increased its stake in Roivant Sciences Ltd. by 147.3% in the fourth quarter, buying 364,390 shares to bring its total holdings to 611,833 shares valued at approximately $13.3 million. Wall Street analysts maintain a \"Moderate Buy\" rating for ", "url": "https://www.marketbeat.com/instant-alerts/filing-centerbook-partners-lp-purchases-364390-shares-of-roivant-sciences-ltd-roiv-2026-06-08/", "source_name": "MarketBeat", "published_at": "2026-06-08T21:39:03", "published_display": "08 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of \"Moderate Buy\" by Brokerages", "summary": "Roivant Sciences Ltd. (NASDAQ:ROIV) has received a \"Moderate Buy\" consensus rating from brokerages, with an average 1-year price target of $33.59. Various firms, including Citigroup and Guggenheim, recently raised their price targets for ROIV, despite a slight downgrade from Weis", "url": "https://www.marketbeat.com/instant-alerts/roivant-sciences-ltd-nasdaqroiv-given-consensus-rating-of-moderate-buy-by-brokerages-2026-06-04/", "source_name": "MarketBeat", "published_at": "2026-06-06T09:40:21", "published_display": "06 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ROIV Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article analyzes the financial performance of Roivant Sciences Ltd (ROIV), focusing on its revenue breakdown, profitability margins, and a comparison with competitors like INSM and INCY. ROIV exhibits a strong gross margin but negative operating and net margins, alongside a ", "url": "https://intellectia.ai/en/stock/ROIV/financials", "source_name": "Intellectia AI", "published_at": "2026-06-02T21:39:58", "published_display": "02 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Roivant\u2019s (ROIV) Profitable Quarter and $982 Million Shelf Filing Just Reframe Its Capital Strategy?", "summary": "Roivant Sciences (ROIV) recently reported a profitable fourth quarter with net income of US$302.99 million, despite only US$2.52 million in sales, contrasting with a full-year net loss. Concurrently, the company filed a US$981.62 million shelf registration for potential share iss", "url": "https://www.sahmcapital.com/news/content/did-roivants-roiv-profitable-quarter-and-982-million-shelf-filing-just-reframe-its-capital-strategy-2026-06-01", "source_name": "Sahm", "published_at": "2026-06-02T05:41:13", "published_display": "02 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (ROIV) Stock Report: Analyzing The 30.18% Potential Upside", "summary": "Roivant Sciences Ltd. (ROIV) is gaining investor attention with a market capitalization of $21.57 billion and a strong analyst consensus pointing to a 30.18% potential upside. The biopharmaceutical company, based in the UK, is focused on drug discovery and development, with lead ", "url": "https://www.directorstalkinterviews.com/roivant-sciences-ltd-roiv-stock-report-analyzing-the-30-18-potential-upside/4121252748", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-01T10:18:00", "published_display": "01 Jun 2026 10:18", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum", "summary": "Roivant Sciences (ROIV) is in focus after strong Phase 2b results for IMVT-1402 and recent earnings, leading to a significant year-to-date share price return. The company is considered 16.3% undervalued by some narratives, with a fair value target of $35.71, driven by a late-stag", "url": "https://www.sahmcapital.com/news/content/roivant-sciences-roiv-valuation-after-strong-imvt-1402-data-and-late-stage-pipeline-momentum-2026-05-29", "source_name": "Sahm", "published_at": "2026-05-29T18:09:20", "published_display": "29 May 2026 18:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. - Common Shares (NQ: ROIV)", "summary": "This article provides financial news and press releases related to Roivant Sciences Ltd. (NQ: ROIV). It highlights recent stock performance, company announcements such as the unveiling of Priovant Therapeutics and ongoing registrational studies, and the announcement of 2021 Open ", "url": "https://markets.financialcontent.com/stocks/quote/news?Symbol=NQ%3AROIV&CurrentPage=3&ChannelType=PRESSRELEASES&CSSURL=36.htm", "source_name": "FinancialContent", "published_at": "2026-05-29T15:10:05", "published_display": "29 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (NasdaqGS:ROIV) Stock Forecast & Analyst Predictions", "summary": "Roivant Sciences (NasdaqGS:ROIV) is forecast to grow earnings and revenue by 50% and 53.9% per annum respectively, although it is expected to remain unprofitable for the next three years. Analysts have frequently updated price targets and revenue estimates based on clinical trial", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/future", "source_name": "Simply Wall Street", "published_at": "2026-05-27T20:39:53", "published_display": "27 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "J.P. Morgan Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $40", "summary": "J.P. Morgan has reiterated its Buy rating on Roivant Sciences (ROIV.US) and increased its target price for the company's stock to $40. This move signals continued confidence from the financial institution regarding Roivant Sciences' future performance and valuation.", "url": "https://www.moomoo.com/news/post/70586721/jp-morgan-maintains-roivant-sciences-roivus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-05-27T15:10:05", "published_display": "27 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing", "summary": "A recent SEC filing revealed that a Roivant Sciences insider sold shares totaling $6,054,000. This transaction could be of interest to investors tracking insider activity and fundamental company developments.", "url": "https://www.moomoo.com/news/post/70552057/roivant-sciences-insider-sold-shares-worth-6054000-according-to-a", "source_name": "Moomoo", "published_at": "2026-05-26T14:08:42", "published_display": "26 May 2026 14:08", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOOUZOUXVDdmE1VHk0QzlMbU5oN3cyNzUwUU5LckV0QmZzZk0zblR5WUVHQVRnWlJfMVhHd1hNZ3JXVmZyT0JSUUNFdGtCYWJybVQ3MW9LMHoxb3VQWjB2dlE1Mmgwbl93cGdNR041eVpBQW01YmdjODl1aUFOSXlyOGR3R1dWVmEwVjA0bGhpakJWNlFaTDF1UGJhXzU4Q1FNa1JpOG1JSHFFUQ?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen Raises its Price Target on Roivant Sciences (ROIV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPLVBwYjZDMkNWTTNfS1oyUXZCSjJQeGY2cmU4SkV5T0ptTnFQOHNMc2g1NWowVHkyVEt4UmhHblI0aXFXQ2podVFxS0FlaTg1ZThPa1JpU0FBZUF6ZkZtQXV3TUVUeDRrSHZuT1l4cVkwcGVKcGNrTkpTNmFtdW9NTUE3ZkFTb3I3YTRFN1lQV09zWTlGVWpPYg?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Litigation Windfall Driving Roivant Sciences\u2019 Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVEt0ZnhaaUZlQ3ozNVpIb2JPeTVtTUhscnAzZE1GTlo5Nng0SXExOHMtMXNaTXd2NHBpdXpwTWFKcUkxSExVYjB4dzlxS2c0bDdraU5XejhicE5xTWNxQjlTX1Y5ZVoybktJbW1WMWFRR3ZsY082SFZheGdUQWx3czdHOWJCODhXNEQxZFMtZUhjZGRlY096R2stSVVPRFZUWTVRYm82ZkU3b0dxTnc?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen raises Roivant Sciences stock price target to $41 on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPcTJuaFlqWlkwVUphUkZGZk5JQlMxTHQ2RFdMSmd2X0hBUlpMUGQtZmFWR3NVbGNvOGlPRDdKcXRoVEhrNThrazRSN0s2eWlBR2syV2F5M21pdENDNzRSbmhxaVUxYm1SSWZPTG96UUVGY0t3QWFnOGR1bTltempMSVlqRE9ENUFFSFNVNUJmTnEzdzhmSVpxVm1jb1JxX3lZMDZPc2lIYzRPYjlRYUxrWEhCYU5xemlJc1dfeGJGaUFYZ0NmTGY1XzFERQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant (ROIV) Climbs 15% on Swing to Profits", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOX08xOE5IRGwzT2ZjV0g2ZVJRYmZ1QUh2Qm1yS0xITVQwbks4VzhLcUZyUnpZT29vdWl4SzVUY1VXRVdZdW1SVGRJVUVMaldPSnJFNVNrRE9vMWNHbGtFbV84M3ZCMFZqblhORWxJUGVfYnI4MXpEbHR5dmlhejMwNWhhUDM1NmJKb1UxbERLZUxzVXE4ZmJwRw?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant (NASDAQ: ROIV) books $770M legal gain and holds $4.3B cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOSHNaMmZHLV9oSHg5cHBhNVgyRllmUnBsLUtFbE4yWEM4TFR2aks3SHR5b0NaUGl4NUh3VEVEQVBXeFJXYXBZRDNJYUVlN1VDQ0haOW1wYThQV01feWxHX1NlaFJfcC01TjZ3YzFFNUlRZU5ETTIzZkJiYmhDeExvdzNpaVpLWktHVFlLWjhGWXB4VE94NUt4QXcwY3FpWUtTcUlKWjBybVJ5WUpGQUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTzJXMDZaS21Hck1pbDg2RDRjM0w2VGdZSFBrTjFram90TGFEWUYyZkhidXpzZ25hYW54YnlyTUZHMmtBbG9POUpOUW53S3NFcGJiTVNrMDdJUTg1cU1WckVOUlh2NmZSQTFKeDlFOHNldmRkaktvSnNFSU5SaVdreVVuQUVMdTB1em5CaS1WU2VRZGx2YzhqYnpwUXlPZWhuaW1OVk13?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Roivant Sciences (ROIV) Story Is Shifting After Settlements And Brepocitinib Milestones", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVXh3WTJ1cEJrZUk5UmQ1V3l6aFlyT201ZHI5Tk5KNFNTOFV2ZFVvM3pzOTVSeFdpdTF0cGRMOEJhNVYtUllJWWNHWXFWQjA1RVFFVFBVRnBrTzRHT3J6TEZjNTRhallvUTA3N2pRRUtWSFhleFUtYzYwdTVkM2tLSVNVTUhhZVZNTHRLU0wtOS1WMUk5RGVGTkFjSDlFTjUxSEpv?oc=5", "source_name": "Market source", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Roivant Sciences (ROIV) Valuation After Encouraging Phase 2 Brepocitinib Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQU1ZHNHpTbHJkakhBX21FMnREVlF2bnNYUEUyOUlKRFRwbHdiZU1ZWURBYTNVWFJ2VTJSejJzNHVUc3A2RVJ4c2QtWTNiSXptTE0xeEROM05YNEZEWHJSZ1VOdmFraHJYdjlUck9mc0Z4TDA0UzliUzNRN0JIdlUwT01jQl9DYm1TWUw0LTM4TFNfQ2s3akhmVkdSVVBpX25KNmpF?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNTWRkaTZzbDJGckxXVFl6QVJzZURfNXNsenRwSUVtdHZGeEk0VnVZczAxQUZva183dk9QZjgwcjFaajRpTDhrcXN1TFliWVVIZUxmTnFmcTE1aDN0NVRhUHVzNUxMbm55OEhOZkw3SGQzUlZyMG5IdlhadkluZkNsUnpkU2R1X0JIaUd2N0F5ZndNU0tzR2VwYWFB?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bernstein initiates Roivant Sciences stock with outperform rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxON2JxSmhwWHJMWWVDOEZzT3lxaUlvaC1mWllmYlJRMGZzSVVoZFRoZHJDSXVabkZkekZxMGw0TkFXT1R1OFJPYXlHZzI1MFBPcXc5T2dFUWE5UUFpZEJ0V1R3eGo2WVVNalh5a191UzA4cndQall1cUdScUl1dlg3aDNBN3NjcnIxOENHR3lzdGpDWXgyRVNnVE9Tek9BZk5ydDh1TVByTzZzang1SVFRZWh0TXhpNS02UnBVeGVTaktvZmc?oc=5", "source_name": "Investing.com", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNRlBObFdWb2lyLWJhN3V3NWpNZ3JIZjFHSXZxRS0tcVFuN1RuRzRWamlJQjhEZS1uMEVzZWQ4cllTTUNfa0YtamxTLUpTU0U4R1dhMEc3S1RNOXkyazJVUEJ3b2hQTVAwQWtxNS1zLUEybVpOYTBRbHAySFBYREtGbXBnazMtNEtRdnVJV2lvaF9kYlVWWTM0MVZ1UGh6QmdyQmdaaHFlMWJaNHNuOHA4MUR3cTd5MkRsVGU5bUdsTkJGajQyVGZB?oc=5", "source_name": "Investing.com", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant unit lands up to $2.25B in Moderna COVID vaccine patent deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOOTR1S3F2aTQ4QVltTDN1MEl5VFhnU2FtZjVfUUpZNDBmY2RnNFFLUG5hTk5jN1A2cjAzRG1SSDdzamJsM2ZsMW9jcTJpSFpNcHRrLXFKZVFxelJ6Ql9MUG1wdm9VeTR0M2g0VFhBX2NobVV3UjB2ZTJlUzY5Vnl6UVhDbFZNTjctRmNyaTZBRGxnSEZ2MzRQeGpDWGVNMTFRTVEzM08tT2xCRXNVOXlBVXlZZTVTODVWSjYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies reiterates Roivant Sciences stock rating on pipeline progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPTUtyUVpEMEZUZXFwNkllaml0N2oxUHZHNFQ0bEpHRUtNWWJ6dFlEOTlUTGhETkE1bHk3WmVDT0Z0QWVsT01xbFpPN3Q1WkFZZmJQakdsVi0ycVROdzJEUXVMTktSTTd6c0dkNlJISnNjRlhjaHV3TkxMeF9vSjY4b0tLelRheVJOV2o1Ykk1RGxDTVJDYzBtR1diZWhhZXd3ak5zZS1OamlOcnNmUFZrWlZ3dGZwRjB6MkV3dUhSV2dZWkRpOUd0OF9pZw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences (ROIV) Valuation Check After Strong Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxOSWtKOGRYTmJZeVlXd0pyVlVKS05KVDZuaEotaU1TbWlpdkFnUzB3Slh6OTJXanV6OGtTakdKRGp6WjNuM2V3bVU3dUNxRE1lWndWdWlnRnRMWWRjVEs1eElwdXJqYlRNSUlPTHRULUI0MjRKSkpnRzlzLU84eDcyWjFMUjZCUWhtVnlj?oc=5", "source_name": "Market source", "published_at": "2026-02-08T08:00:00+00:00", "published_display": "08 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Roivant Sciences Stock Gain 9% Pre-Market Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPbUtkZlJPS3dLOERyUm5lZGRWZXgzYkswdGJHNWhHQW9VSUZ1ekxERFJXZmhxWklkMWtqM2NVNnNQLUY2VXJISGFMdUhJblNXY2VFMTdmZDREaXlkbUZLa2FhQWEyblJrT25ybkpvVklpeHhkamt4azVPSWtxTFhwTEF5ZDU1S2tES2RYNWhpUy1TX3QwN01IQ3pvN2hnYjdvdHYySTBLTUtXNUY0S3VLS2d3Q2RoWjA?oc=5", "source_name": "Stocktwits", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Roivant Sciences misses Q3 2026 estimates despite stock surge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNQkZuVmMtNWpvdjFsN2VGZk9xdU1wdGZycmcwbXhDZFVWM0tRWnI3UFAxN01QdXhGSFNoV1RCY0NPQ1RLRjE1MHduc3NqZTN5RnJnT2FDMXN5RGZaaHhhVXF5dVd3R3JDZUlYaURSbDZjOVVkcVZZaG85RHR3U09IZjNjc3hHaHFsb19tUm1nLWVWaUhoMUVsczRnaklZMFJhcmlfRTdlc1gzSFJtYXJ1QWJ3SFpPR0Voend0N2J3MWw4Y0YzZG9ScnVfbFlPWC1FYm1LRXptVTFDdw?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roivant Sciences: King Of The Vants Prepares To Drop Vantism In Search Of Greater Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOaDBEUURhTU04V0hHaEZLTXFGQTN4SU9YckJnMWN6V0FWVHY2Q0dVMmEwVEc0V3EtU0xWUmh4TTZZSkx0YUcxRHo3TWI2Z0lKekxyUTR1QlZOUDZJOHY0UzZicmw0R3RmTHNEZ1JhdGZDUUgtTWFlM0Q5dkh3WlVfR053VnFKOVl4WVpEM1hNdFJGY0R3bDQ0dVhYa3BrQ181LVNpYjU0dFV1eGtyTTUwcFBCbU5zZjl6ZnpCZDRRaWhZU2s3dEl3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 96, "total_relevant": 55, "sentiment_summary": {"positive": 30, "negative": 3, "neutral": 22, "score": 60, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 73, "events": [{"event": "earnings", "label": "Earnings", "weight": 10.59, "count": 21}, {"event": "general", "label": "Market update", "weight": 10.25, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 6.6, "count": 12}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 30, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 31.43, "latest_week": "2026-06-19", "one_week_move": 4.6, "four_week_move": 4.9, "twelve_week_move": 18.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.495855, "market_dynamics_buy_signal": false, "relative_strength": 23.707676, "fair_value_gap": 117.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 57.5997, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.6% over one week, +4.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "MarketBeat", "count": 6}, {"label": "Investing.com", "count": 5}, {"label": "Insider Monkey", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Moomoo", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 21}, {"label": "Market update", "count": 18}, {"label": "Analyst action", "count": 12}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.6% over one week, +4.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "What Roivant Sciences (ROIV)'s $2.25 Billion Moderna Settlement and Immunology Wins Mean For Shareholders"}], "updated_at": "2026-06-22T10:41:32.143495+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}